Abstract
To examine potential cost-effectiveness of Alzheimer’s disease-modifying therapies (DMTs) of different treatment durations. BACKGROUND: Clinical trial results suggest the disease-modifying impact of a new class of anti-amyloid monoclonal antibodies. Optimal treatment duration is uncertain due to limited follow-up in clinical trials. A recent economic analysis of the first such agent approved questioned the economic value of treatments that slow progression of early symptomatic Alzheimer’s disease (AD) to more advanced states.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
